Add-On Therapy of Dapagliflozin to Metformin in Patients with Diabetes Mellitus Type-2; Efficacy and Renal Safety

Abstract

Objective: To study efficacy of Dapagliflozin in treatment of diabetes mellitus type-2.

Study Design: Quasi-experimental study.

Place and Duration of Study: Medical unit, Benazir Bhutto Shaheed Hospital, Rawalpindi Pakistan from Jan to Dec 2019.

Patients & methods: Patients taking Dapagliflozin in combination with Metformin (MET+DAPA) (n=45) were compared to
those taking other glucose lowering agent in combination with Metformin (MET+ other drug) (n=45) for the control of
diabetes mellitus type-II. Efficacy of treatment was assessed by the level of glycosylated hemoglobin HbA1c, and renal safety assessed by serum creatinine level done at 6 and 12 months of treatment.

Results: Total 90 cases were studied including 60% male and 40% female cases with mean age 50.8±7.4 years. Patients taking Dapagliflozin + Metformin (n=45), and others taking Metformin+ other glucose lowering drug (n=45) were having mean values of BMI 32.8±5.9 kg/m2 & 33.4±7.2 kg/m2, HbA1c 8.4±1.2% & 9.1±1.6 % and blood urea nitrogen 6.7±1.4 & 6.5±1.8 mmol/L respectively. After 12 months treatment mean HbA1c level was reduced from 8.7 ± 1.4% to 6.6 ± 0.3%, BMI reduced significantly and no detrimental effects reported on renal function.

Conclusion: Patients with type-II diabetes mellitus taking Dapagliflozin in combination with Metformin showed good
glycemic control and renal safety.